Thromb Haemost 2003; 90(04): 704-709
DOI: 10.1160/TH03-04-0203
Vascular Development and Vessel Remodeling
Schattauer GmbH

Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells

Ellen Bretschneider
1   Institut für Vaskuläre Medizin Erfurt, Friedrich-Schiller-Universität Jena, Germany
,
Rainer Spanbroek
1   Institut für Vaskuläre Medizin Erfurt, Friedrich-Schiller-Universität Jena, Germany
,
Katharina Lötzer
1   Institut für Vaskuläre Medizin Erfurt, Friedrich-Schiller-Universität Jena, Germany
,
Andreas Johann Richard Habenicht
1   Institut für Vaskuläre Medizin Erfurt, Friedrich-Schiller-Universität Jena, Germany
,
Karsten Schrör
2   Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Germany
› Author Affiliations
Financial support: This study was supported by the Interdisziplinärer Verbund für Klinische Forschung of the Friedrich-Schiller-Universität Jena and the Deutsche Forschungsgemeinschaft (SFB 612, B7 and Ha 1083/13-1/13-2) and the EU research network (QLG1-CT-2001-01521).
Further Information

Publication History

Received 01 April 2003

Accepted after resubmission 19 May 2003

Publication Date:
05 December 2017 (online)

Summary

The present study investigates whether vascular smooth muscle cells of the human saphenous vein (SMC) express a functionally active protease-activated receptor-3 (PAR-3). PAR-3 mRNA was detected by RT-PCR. In the presence of thrombin, a rapid and transient increase in PAR-3 mRNA was observed. Stimulation of SMC with thrombin or the synthetic PAR-3-activating peptide, TFRGAP, resulted in transient mobilization of intracellular calcium. After a preceding challenge with thrombin, the calcium signal to TFRGAP was abolished, suggesting cleavage and subsequent desensitization of PAR-3 by thrombin. Activation of PAR-3 by TFRGAP elicited a time-dependent activation of the extracellular-signal-regulated kinase (ERK)-1/2 with a maximum response 10-20 min after stimulation. At 200 µM, TFRGAP increased 3H]-thymidine incorporation into cellular DNA about two-fold. These data indicate that PAR-3 is expressed in human SMC and triggers intracellular signaling. Thus, in the SMC PAR-3 might contribute to thrombin-induced responses.

 
  • References

  • 1 Vu TK, Hung DT, Wheaton VI. et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
  • 2 Ishihara H, Connolly AJ, Zeng D. et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-6.
  • 3 Xu W-F, Andersen H, Whitmore TE. et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998; 95: 6642-6.
  • 4 Faruqi TR, Weiss EJ, Shapiro MJ. et al. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000; 275: 19728-34.
  • 5 Hauck RW, Schulz C, Schömig A. et al. Alpha-thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors. Am J Physiol 1999; 277 1 PT 1 L22-29.
  • 6 Wang H, Ubl JJ, Reiser G. Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 2002; 37: 53-63.
  • 7 Kaufmann R, Junker U, Nuske K. et al. PAR-1 and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int J Oncol 2002; 20: 177-80.
  • 8 Nakanishi-Matsui M, Zheng Y-W, Sulciner DJ. et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404: 609-13.
  • 9 Sambrano GR, Weiss EJ, Zheng Y-W. et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-8.
  • 10 Schmidt VA, Nierman WC, Maglott DR. et al. The human proteinase-activated receptor-3 (PAR-3) gene. J Biol Chem 1998; 273: 15061-8.
  • 11 Cupit LD, Schmidt VA, Bahou WF. Proteolytically activated receptor-3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Trends Cardiovasc Med 1999; 9: 42-8.
  • 12 Kahn ML, Nakanishi-Matsui M, Shapiro MJ. et al. Protease-activated receptor 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-87.
  • 13 Bretschneider E, Kaufmann R, Braun M. et al. Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol 2001; 132: 1441-6.
  • 14 Bretschneider E, Braun M, Fischer A. et al. Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells. Thromb Haemost 2000; 84: 499-505.
  • 15 Kanthou C, Benzakour O, Patel G. et al. Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells. Thromb Haemost 1995; 74: 1340-7.
  • 16 Macfarlane SR, Seatter MJ, Kanke T. et al. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-82.
  • 17 Hollenberg MD, Compton SJ. International union of pharmacology. XXVIII. proteinase-activated receptors. Pharmacol Rev 2002; 54: 203-17.
  • 18 Ishii K, Chen J, Koch WJ. et al. Inhibition of thrombin receptor signaling by G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases. J Biol Chem 1994; 269: 1125-30.
  • 19 Hoxie JA, Ahuja M, Belmonte E. et al. Internalization and recycling of activated thrombin receptors. J Biol Chem 1993; 268: 13756-63.
  • 20 Hammes SR, Coughlin SR. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PAR1’s tethered ligand. Biochemistry 1999; 38: 2486-93.
  • 21 Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999; 19: 2435-44.
  • 22 Shapiro MJ, Weiss EJ, Faruqi TR. et al. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000; 275: 25216-21.